INFLAMMATORY BREAST NEOPLASMS: A SYSTEMATIC REVIEW

Autores

  • Naidhia Alves Soares Ferreira Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil./Faculdade de Juazeiro do Norte, Juazeiro do Norte – CE, Brazil.
  • Sionara Melo Figueiredo de Carvalho Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil./Universidade Federal doCariri, Barbalha-CE, Brazil.
  • Cintia de Lima Garcia Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil./Faculdade de Juazeiro do Norte, Juazeiro do Norte – CE, Brazil.
  • Grayce Alencar Albuquerque Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil./Faculdade de Juazeiro do Norte, Juazeiro do Norte – CE, Brazil.
  • Vitor Engrácia Valenti Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil.
  • Thaiany Pedrozo Campos Antunes Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil.
  • Hugo Macedo Jr. Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil.
  • Luiz Carlos de Abreu Laboratório de EscritaCientífica da Faculdade de Medicina do ABC, Santo André –SP, Brazil.

DOI:

https://doi.org/10.7322/jhgd.88974

Palavras-chave:

inflammatory breast neoplasms, medical oncology.

Resumo

Overview: Inflammatory Breast Cancer (IBC) is a rare and very aggressive type of cancer that tends to develop at a younger age, compared with other subtypes of breast cancer. Because a distinct lump may not be noticeable, correct diagnosis takes longer and, therefore, successful treatment may hinder a patient’s prognostics. This study aims to conduct a systematic review of research articles on IBC. Methods: This is a systematic review of studies in the PubMed database to April 2013, which fit the eligibility criterion of “Inflammatory Breast Neoplasms” (MeSH Terms), filtered by Languages (English OR Portuguese OR Spanish). Findings: Of the 119studies identified, 25 complied with the eligibility criterion for the disease, diagnostics, treatment and prognostics. Final Considerations :Despite methodological differences, findings evidence that although IBC presents particular features (lower survival rate and worse prognostics than most types of breast cancer), very few studies examine its epidemiology and specific risk factors in depth and use any other therapeutic approaches than those commonly used for other breast cancer subtypes. Therefore, further investigation of the disease’s aggressiveness is still necessary.

Referências

Hani K. Atrash 1, Richard Carpentier The evolving role of public health in the delivery of health care. Journal of Human Growth and Development, 2012; 22 (3): 396-99.

Ariana Machado Toriy, EditKrawulski, Jaqueline de Souza Viera Brasiliense, Clarissa Medeiros da Luz, Fabiana Flowers Sperandio. Perceptions, feelings and physical and

emotional experiences of woman after breast cancer. Journal of Human Growth and Development, 2013; 23 (3): 303-08.

Arias-Pulidoet al. Tumor stromal vascular endothelial growth factorA is predictive of poor outcome in inflammatory breast cancer BMC Cancer 2012, 12:298.

Nouh, M. A. et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. Journal of translational medicine9, 1, doi:10.1186/1479-5876-9-1 (2011).

Andic, F. et al. Treatment adherence and outcome in women with inflammatory breast cancer: does race matter? Cancer117, 5485-5492, doi:10.1002/cncr.26187 (2011).

Hance KW, A. W., Devesa SS, et al. Trends in, the, i. b. c. i. a. s., surveillance, e., and end results program at the, 2005;97:966-, N. C. I. J. N. C. I. & 975.

Moher D, L. A., Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

Ye, Y., et al. (2010). E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.Anticancer Research, 30(10), 3903-10.

Gong, Y. et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breastcancer and is predictive of worse clinical outcome. Cancer117, 5476-5484, doi:10.1002/cncr.26179 (2011).

Le-Petross, H. T. et al. MRI features of inflammatory breast cancer. AJR. American journal of roentgenology197, W769-776, doi:10.2214/AJR.10.6157 (2011).

Dawood, S. et al. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO21, 2348-2355,

doi:10.1093/annonc/mdq239 (2010).

Dawood, S. et al. Identifying factors that impact survival among women with inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO23, 870-875, doi:10.1093/annonc/mdr319 (2012).

Victor, B. C., Anbalagan, A., Mohamed, M. M., Sloane, B. F. & Cavallo-Medved, D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast cancer research: BCR13, R115, doi:10.1186/bcr3058 (2011).

Thomas, Z. I. et al. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. British journal of cancer104, 1575-1586, doi:10.1038/bjc.2011.133 (2011).

Shin, H. J. et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. The British journal of radiology84, 612-620, doi:10.1259/bjr/74430952 (2011).

Allensworth, J. L., Aird, K. M., Aldrich, A. J., Batinic-Haberle, I. & Devi, G. R. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Molecular cancer therapeutics11, 1518-1527, doi:10.1158/1535-7163.MCT-11-0787 (2012).

Schairer, C., Brown, L. M. & Mai, P. L. Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast

cancer. Breast cancer research and treatment129, 117-124, doi:10.1007/s10549-010-1324-y (2011).

Mandal, P. K., Freiter, E. M., Bagsby, A. L., Robertson, F. M. & McMurray, J. S. Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells. Bioorganic & medicinal chemistry letters21, 6071-6073, doi:10.1016/j.bmcl.2011.08.050 (2011).

Martinez-Montemayor, M. M., Acevedo, R. R., Otero-Franqui, E., Cubano, L. A. & Dharmawardhane, S. F. Ganoderma lucidum (Reishi) inhibits cancer cell growth and

expression of key molecules in inflammatory breast cancer. Nutrition and cancer63, 1085-1094, doi: 10.1080/01635581.2011.601845 (2011).

Schlichting JA, et al. Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.Cancer Epidemiol Biomarkers Prev 21, 155.doi: 10.1158/1055-9965 2012.

Chaher, N. et al. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast cancer research and treatment131, 437-444, doi:10.1007/s10549-011-1422-5 (2012).

Li, J. et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. The oncologist16, 1675-1683, doi:10.1634/theoncologist.2011-0196 (2011).

Ohshiro K, Schwartz AM, Levine PH, Kumar R. Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic Signaling. PLoS ONE 7(1): e30725. doi:10.1371/journal.pone.0030725 (2012).

Bertucci, F. 8q24 cancer risk allele associated with major metastatic risk in inflammatory breast cancer. PLoS One 7(5),doi:10.1371/journal.pone.0037943.t001 (2012).

Duke T J, Nasreen C. Jahed, C C. Veneroso, R R, Owen J, Daniel H. et al. A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology.

Oncology reports24, doi:10.3892/or_00000983 (2010).

Bourgier C et al. Exclusive Alternating Chemotherapy and Radiotherapy in Nonmetastatic Inflammatory Breast Cancer: 20 Years of Follow-Up. International Journal of

Radiation Oncology, Biology, Physics 82(2) 690-695, (2012).

Sezgin C et al. p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. Med Princ Pract 20(2):159-64. doi: 10.1159/

(2011).

Mailliez et al. Is there a reliable method to assess the complete pathologic response on the tumor after eo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? Experience in 56 patients treated in a single institution. Breast J 16(5):464-71. doi: 10.1111/j.1524-4741.2010.00957 (2010).

Schlichting JA, et al. Inflammatory and noninflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.BreastCancer Res Treat 134(3), 1257-68(2012). 29

Downloads

Publicado

2014-12-17

Edição

v. 24 n. 3 (2014)

Seção

Pesquisa Original

Licença

CODE OF CONDUCT FOR JOURNAL  PUBLISHERS

 

Publishers who are Committee on Publication Ethics members and who support COPE membership for journal editors should:

 

Publishers should:

 

  • Define the relationship between publisher, editor and other parties in a contract
  • Respect privacy (for example, for research participants, for authors, for peer reviewers)
  • Protect intellectual property and copyright
  • Foster editorial independence

 

Publishers should work with journal editors to:

 

  • Set journal policies appropriately and aim to meet those policies, particularly with respect to:

–         Editorial  independence

–         Research ethics, including confidentiality, consent, and the special requirements for human and animal research

–         Authorship

–         Transparency and integrity (for example, conflicts of interest, research funding, reporting standards

–         Peer review and the role of the editorial team beyond that of the journal editor

–         Appeals and complaints

  • Communicate journal policies (for example, to authors, readers, peer reviewers)
  • Review journal policies periodically, particularly with respect to new recommendations from the COPE
  • Code of Conduct for Editors and the COPE Best Practice Guidelines
  • Maintain the integrity of the academic record
  • Assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases
  • Publish corrections, clarifications, and retractions
  • Publish content on a timely basis